Measuring Serum BCMA for Non-Secretory Myeloma Patients with Dr. James Berenson image

Measuring Serum BCMA for Non-Secretory Myeloma Patients with Dr. James Berenson

Jun 16, 2022
07:00PM - 08:00PM EDT
Online Event
Overview

Non-secretory myeloma patients are hungry for other ways to monitor their disease apart from a bone marrow biopsy. Thankfully, research in myeloma has discovered a possible way to make that happen. Join Dr. Berenson as he expounds on what he and his team have found regarding the measuring of non-secretory myeloma through Serum BCMA blood markers. Come with your questions!

Agenda
07:00 PM
Introduction
Audrey Burton-Bethkee
Audrey introduces the agenda of the event and featured speaker Dr. Berenson
07:05 PM
Presentation
Dr. James Berenson
Dr. Berenson shares about how serum BCMA can be measured to potentially track nonsecretory myeloma.
07:35 PM
Questions and Answers
Audience
Type your questions in the chat and we will answer them!
Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Dr. James Berenson

Dr. James Berenson

Dr. Berenson founded the Institute for Myeloma & Bone Cancer Research (IMBCR) in 2003 and serves as its Medical and Scientific Director: A mission-driven 501(C)3 non-profit institute is committed to advance the monitoring and treatment of multiple myeloma (MM) by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care. Dr. Berenson has authored nearly 300 peer-reviewed publications and contributed to multiple book chapters. He has served as a member of the National Institutes of Health – Center for Scientific Review, Clinical Oncology Study Section and is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. Dr. Berenson has also served on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society. Additionally, Dr Berenson is Section Editor for Supportive Cancer Therapy and on the Editorial Board of: Annals of Hematology, Annals of Oncology, British Journal of Hematology, Clinical Advances in Hematology & Oncology, Clinical Cancer Research, Clinical Lymphoma & Myeloma, Critical Reviews in Oncogenesis, Targeted Oncology, and provides Current Opinion in Supportive and Palliative Care.